Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
LOS ANGELES, Aug. 21, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against IntelliPharmaCeutics International Inc. (“IntelliPharmaCeutics” or the “Company”) (Nasdaq:IPCI) for possible violations of federal securities laws between January 14, 2016 and July 26, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired IntelliPharmaCeutics shares during the Class Period should contact the firm prior to the September 29, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting sufficient data to support approval of the NDA; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. When this news reached the public, shares of IntelliPharmaCeutics lowered in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was established by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
